Novo Nordisk (NVO)
(Delayed Data from NYSE)
$157.98 USD
-2.48 (-1.55%)
Updated Jun 1, 2023 04:00 PM ET
After-Market: $157.99 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
NVO 157.98 -2.48(-1.55%)
Will NVO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVO
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis
Pfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Large Drug Stocks to Watch From a Thriving Industry
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
Novo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion
Other News for NVO
No Record found.